• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

USD 3 Million Awarded to Find Biomarkers for Potential Test of Cure for Chagas Disease

Geneva, Switzerland / Atlanta, USA — 12 Nov 2012

Wellcome Trust to fund three-year study in Texas to look for new biological markers measuring treatment efficacy for the leading parasitic killer of the Americas
Today at the 61st Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), the Drugs for Neglected Diseases initiative (DNDi) announces a new USD 3 million Strategic Translation Award from the Wellcome Trust to identify new biological markers for the evaluation of treatment efficacy in Chagas disease, a potentially fatal neglected tropical disease.

Chagas disease infects approximately 8 million people worldwide and is the leading parasitic killer in the Americas, where it causes more deaths than malaria. There is currently no easy-to-use and reliable test available to assess if Chagas patients are rid of the parasite after treatment, and current treatment options have significant limitations due to poor safety, inconsistent efficacy, and long treatment duration. Determining if treatment has cured the infection requires difficult and lengthy repeat laboratory testing that can sometimes take decades due to the unique chronic nature of the disease. Patients and physicians are often skeptical of the benefit of treatment for the chronic, indeterminate form of Chagas without a direct way to measure cure. A new, robust test for the disease burden would help to expand treatment, as well as provide a valuable tool for accelerating the evaluation of new drugs in clinical trials.

The USD 3 million Wellcome Trust Award will fund the first-ever large-scale study involving treatment of non-human primates (macaques) naturally infected in their outdoor living environment with the parasite that causes Chagas disease, Trypanosoma cruzi. The animals will be treated with three drug regimens versus placebo: benznidazole at optimal dose, benznidazole at suboptimal dose, and another azole compound with anti-parasite activity. Over a period of 12 months after treatment, the animals will be examined for clearance of the Chagas parasite through polymerase chain reaction (PCR) and other blood tests. The primary goal of the study is to see if these blood tests can accurately measure parasitological cure.

“We need to be able to tell patients whether or not their treatment has worked,” said Dr. Graeme Bilbe, Research and Development Director for DNDi. “The results of this study could encourage treating more patients now, with what we have, and facilitate future clinical trials of new treatments for chronic Chagas disease patients.”

Initiated by Dr. John VandeBerg of the Texas Biomedical Research Institute (Texas Biomed; San Antonio, TX) and Dr. Rick Tarleton of the Center for Tropical and Emerging Global Diseases at the University of Georgia (Athens, GA), the study will be coordinated by DNDi with these partners and will begin within months and run until 2015. Texas Biomed will conduct the experimental protocols with the animals and conduct biomarker anlaysis, and the University of Georgia will also perform biomarker analysis. Other partners to perform some of the testing are the University of Texas at El Paso (UTEP; El Paso, TX), Gentris (Morrisville, NC), and the Argentinean National Council of Scientific and Technical Investigation (INGEBI-CONICET). To facilitate future biomarker discovery efforts, the biological samples collected in the study will be stored and made available to other researchers.

Today’s announcement coincides with the first technical project meeting for this study taking place on November 12th at ASTMH’s Annual Meeting in Atlanta.

###

About Chagas disease
Chagas disease is endemic in 21 countries across Latin America, where it kills more people than any other parasite-borne disease, including malaria. It currently infects approximately 8 million people, kills an estimated 12,000 per year, and places 100 million people at risk. Chagas disease is a chronic, systemic, parasitic infection caused by the protozoan Trypanosoma cruzi. In 30-40% of cases, chronic Chagas disease will affect the heart and/or the digestive system. It is potentially fatal and a leading cause of heart failure in Latin America, resulting in frequent and prolonged hospitalization, use of pacemakers and defibrillators, and heart transplants. The disease causes loss of productivity among tens of thousands of young, working-age adults across Latin America, with over a billion dollars (USD) in estimated economic losses annually. As a result of worldwide population flow, Chagas disease is no longer confined to Latin America, with patient numbers growing in the United States, Europe, Australia, and Japan.

About DNDi
The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development organization working to deliver new treatments for neglected diseases, in particular sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, specific helminth infections, malaria, and paediatric HIV. DNDi was established in 2003 by Médecins Sans Frontières/Doctors Without Borders (MSF), the Oswaldo Cruz Foundation (FIOCRUZ) of Brazil, the Indian Council of Medical Research (ICMR), the Kenya Medical Research Institute (KEMRI), the Ministry of Health of Malaysia, and the Pasteur Institute of France. The Special Programme for Tropical Disease Research (WHO/TDR) serves as permanent observer. DNDi currently has one lead drug candidate, E1224 (ravuconazole pro-drug), in clinical development for the treatment of Chagas disease, and two other drug classes in preclinical development.

Since its inception in 2003, DNDi has delivered six new treatments for neglected patients: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease.

DNDi has helped establish three clinical research platforms: Leishmaniasis East Africa Platform (LEAP) in Kenya, Ethiopia, Sudan, and Uganda; the HAT Platform based in the Democratic Republic of Congo (DRC) for sleeping sickness; and the Chagas Clinical Research Platform in Latin America. Strong regional networks such as these help strengthen research and treatment-implementation capacity in neglected disease-endemic countries.
www.dndi.org

About the Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
www.wellcome.ac.uk

Media contact
Oliver Yun, Communications Manager, DNDi North America;
tel: +1-646-266-5216;
email: oyun@dndi.org

Funding Partnership Chagas disease

Read, watch, share

Loading...
Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

Stories
16 Apr 2025

Drug discovery explained: Chagas – How to prove treatments work?

Statements
16 Apr 2025

Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations

Press releases
15 Apr 2025

New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License